Augustine Therapeutics is proud to be sponsoring and participating to the iPSC Modelling in Neuromuscular Disorders (iMND) conference from October 23-25 in Leuven.

Augustine Therapeutics is proud to be sponsoring and participating to the iPSC Modelling in Neuromuscular Disorders (iMND) conference from October 23-25 in Leuven.This conference aims to unite scientists from academia as well as industry who use iPSC-derived models to obtain new insights into various motor neuron diseases.With the support of the US The ALS Association patient advocacy group, Augustine Therapeutic is currently advancing novel and best-in-class, brain penetrant and orally bioavailable selective HDAC6 inhibitors for the potential treatment of motor neuron diseases like Amyotrophic Lateral Sclerosis (ALS)Find out details of the event and agenda here: Click Here